Impact of active surveillance for prostate cancer on the risk of depression and anxiety.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 07 2022
28 07 2022
Historique:
received:
08
12
2021
accepted:
21
07
2022
entrez:
28
7
2022
pubmed:
29
7
2022
medline:
2
8
2022
Statut:
epublish
Résumé
Active surveillance (AS) is a standard treatment option for low risk localized prostate cancer. However, the risk of anxiety and depression compared to other curative strategies, namely radical prostatectomy (RP) and radiotherapy (RT), is controversial. This study consisted in a French representative sample of 4174 5-years cancer survivors. Self-reported data, including quality-of-life assessment, were prospectively collected through telephone interviews. Among the 447 survivors with PC, we selected 292 patients with localized prostate cancer, T1-T2 stage, Gleason score ≤ 7 and we compared anxiety and depressive symptoms according to treatment strategy. Among patients on AS, 14.9% received curative treatment during the 5 years of follow-up. Anxiety was reported in 34.3% of cases in the AS group versus 28.6% in the RP group and 31.6% in the RT group (p = 0.400), while depressive symptoms were reported in 14.9% of cases in the AS group versus 10.7% in the RP group and 22.8% in the RT group (p = 0.770). Consumption of anxiolytics reported did not vary significantly between the 3 groups (p = 0.330). In conclusion, patients managed with AS for localized prostate cancer do not report more anxiety or depressive symptoms than patients managed with curative treatment, encouraging the extended use of active surveillance.
Identifiants
pubmed: 35902716
doi: 10.1038/s41598-022-17224-w
pii: 10.1038/s41598-022-17224-w
pmc: PMC9334351
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12889Informations de copyright
© 2022. The Author(s).
Références
Eur Urol. 2016 Apr;69(4):576-581
pubmed: 26456680
Oncol Nurs Forum. 2003 Mar-Apr;30(2):303-9
pubmed: 12692664
BJU Int. 2013 Jul;112(2):E67-75
pubmed: 23795800
J Urol. 2018 Dec;200(6):1250-1255
pubmed: 29886089
Behav Res Ther. 2009 Mar;47(3):215-23
pubmed: 19159867
Br J Cancer. 2006 Apr 24;94(8):1093-8
pubmed: 16622434
Eur Urol. 2013 Apr;63(4):597-603
pubmed: 23159452
Cancer. 2017 May 1;123(9):1490-1496
pubmed: 28152172
J Urol. 2016 Jun;195(6):1724-30
pubmed: 26872841
Urol Oncol. 2019 Apr;37(4):282-288
pubmed: 30630735
Cancer. 2009 Sep 1;115(17):3868-78
pubmed: 19637245
BJU Int. 2014 Nov;114 Suppl 1:55-61
pubmed: 25070423
BMJ Open. 2015 Mar 24;5(3):e005971
pubmed: 25805526
Rev Epidemiol Sante Publique. 2017 Oct;65 Suppl 4:S149-S167
pubmed: 28756037
Curr Opin Urol. 2015 May;25(3):272-6
pubmed: 25692724
BMJ Open. 2014 Mar 13;4(3):e003901
pubmed: 24625637
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Urology. 2017 May;103:173-178
pubmed: 28189554
N Engl J Med. 2016 Oct 13;375(15):1425-1437
pubmed: 27626365
N Engl J Med. 2016 Oct 13;375(15):1415-1424
pubmed: 27626136
Psychooncology. 2015 Feb;24(2):228-35
pubmed: 24891013
J Urol. 2010 May;183(5):1786-91
pubmed: 20299064
Health Serv Res. 2000 Oct;35(4):885-904
pubmed: 11055454